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Figure 1. Kaplan Meier survival curve of different magnitudes of serum GM
indices (A), and BAL GM indices (B)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312 S289evaluated the impact of different GM cut-off levels in serum
and BAL on mortality. Kaplan Meier curves were used to
estimate survival, and Cox proportional hazardsmodels were
used to evaluate univariate and adjusted hazards ratios for
180 day all-cause mortality associated with different serum
and BAL GM index cutoff values.
Results: A diagnosis of probable IPA was made by a positive
serumGMindex (0.5) alone in32patients andapositiveBAL
GM index (0.5) alone in47patients. In 21patients, the serum
andBALGMindiceswerebothpositive.Overallmortality in all
patients was 52% at 180 days. Patients with a positive serum
GM index at the time of IPA diagnosis had an increased
mortality (60.4%; n ¼ 53) compared to patients with a nega-
tive serum GM index (42.6%; n ¼ 47). In contrast, a positive
BAL GM index had no effect on mortality (Figure 1A,B). In
addition, the magnitude of the serum GM index was associ-
ated with enhanced mortality. When compared to a serum
GM index of  0.5, increasing values of serum GM were
associated with an increased HR of 180 day mortality (serum
GM  1: HR ¼ 2.18 (1.15-4.15); serum GM  1.5: HR ¼ 2.97
(1.53-5.81); serumGM 2: HR¼ 3.68 (1.63-8.30)). This result
was conﬁrmed in a multivariate analysis that adjusted for
acute GVHD, sex, underlying hematologic disease severity,
and elevated creatinine. No association was seen with
increasing magnitudes of BAL GM indices.
Conclusions: This study shows an increased HR for mortality
with increasing cutoffs of serum GM indices, with no corre-
sponding increase in HR with increasing BAL GM indices. We
propose that the initial serum GM index value at the time of
IPA diagnosis represents both an important prognostic
indicator and a valuable covariate in future analyses on
outcomes in HCT recipients.359
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Background: Phase II studies suggested that pts who
received an in-vivo T-cell depleted (TCD) alloSCT with
Alemtuzumab (AL) tended to have less aGVHD.However, the
utility of this approach is limited by increased incidence ofmixed chimerismwhich is associated with increased disease
recurrence and often require DLI.
Hypothesis:We hypothesize that sub-optimal CD 34 +ve cell
dose contribute to mixed chimerism after an in-vivo TCD
alloSCT using AL. By identiﬁng an optimal CD 34 +ve cell
dose; an in-vivo TCD protocol could maintain the beneﬁt of
lowering the incidences of GVHD and minimize mixed
chimerism. We also evaluate other patient & treatment
characteristics that may contribute to mixed chimerism.
Method: We conducted a retrospective study to evaluate the
impact of CD 34 +ve cell dose and patient and treatment
characteristics on T-cell and Myeloid chimerism after an in-
vivo TCD alloSCT. Between 5/11 & 5/12, 32 consecutive pts
underwent an in-vivo TCD alloSCT. F/M: 18/14. The diagnosis
included 21 AML/MDS, 4 NHL, 3 MDS & 7 others. Conditioning
regimensconsistedofFludarabine/Melphalan:22, Fludarabine/
Busulfan: 7 and others in 3. Upon achievement of engraftment,
wemonitorengraftmentbyShort tandemrepeatmonthlywith
T-cell andMyeloid subsets analysis.We utilize of AL for in-vivo
TCD (20MRD: 30mgonDay -1; 12MUD: 30mgdaily onDay -2
& Day -1). All patients also received cyclosporine.
Results: Pts received a median of 4.96 x 10e6 per kg CD 34
positive cells (range 2.45 e 27.22). 30/32 pts achieved
neutrophils engraftment except 1 died shortly after SCT from
CHF & 1 experienced primary graft failure with day 30 STR
showing only 3% donor T-cell chimerism. On Day 30 post-
SCT, all evaluable pts had predominately donor T-cell
(median 99%; 22/31 (71%)  99%; range 82 to > 99%) and
Myeloid Chimerism (28/31 (90%)  99%. 25 pts survived
beyond Day 90 and have engraftment data available for
analysis . Between Days 90 & 120 analysis, most pts maintain
predominant donor myeloid chimerism (> 95%; median
99%); only 11/25 (44%) had maintained  91% donor T-cell
chimerism. 7/25 (28%) and 7/25 (28%) had 71-90 % and 70%
donor T-cell chimerism respectively. CD 34 +ve Cell dose,
disease type, disease status, prior treatment, age, sources of
stem cells (MRD vs MUD) and conditioning regimen did not
predict for mixed chimerism. While 43% of the patients
received Melphalan/Fludarabine; 60% of the patients
received a busulfan/ﬂudarbine had donor T-cell chimerism
dropped below 80% between day 90-120. Five pts (17%)
developed acute GVHD with only 1 (4%) Grade IV aGVHD.
Conclusion: 1. Mixed chimerism is common after in-vivo
TCD alloSCT; 2. CD 34 Cell dose, disease type, prior treatment,
age, sources of stem cells and conditioning regimen did not
predict for mixed chimerism & 3.The high incidences of
signiﬁcant mixed chimerism (< 80%) on day 90 in pts
received Bu/Flu is of concerns that warrant close monitoring
in future studies.360
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Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312S290Introduction: Allogeneic Hematopoietic Stem Cell Trans-
plantation (HSCT) is indicated for patients with intermediate
or high risk primary Myeloﬁbrosis (MF), and also in patients
with Policitemia Vera or Essential Thrombocythemia who
have progressed to high risk MF. The results for allogeneic
HSCT with myeloablative conditioning seem to be better for
patients younger than 45 years, determining lower relapse
risk. However, Reduced Intensity Conditioning (RIC) for
patients between 45 and 65 years-old has shown to be
a promising strategy, with less mortality related to the
procedure. This study aims describing a series of patients
diagnosed with myeloﬁbrosis, transplanted in the Hospital
de Clínicas (HC) from the Federal University of Paraná and
Hospital Nossa Senhora das Graças (HNSG) (Curitiba, Brazil).
Patients and Methods: From 1984 to 2011, fourteen patients
with MF were submitted to HSCT, eleven from the HC and
three from HNSG. The median of age was 42 years (10-51).
Therewere ten males and four females. In average, ﬁve blood
transfusions were done per patient (0-61). Five male patients
received the graft from a female donor, and two patients
received an unrelated HSCT. The median of duration of the
disease was 20 months (2-150). According to Dupriez Clas-
siﬁcation, all the patients were of intermediate and high risk.
Five patients had a myeloablative conditioning (Busulfan
plus Cyclophosphamide: 4; Cyclophosphamide plus Total
Body Irradiation:1) while nine had a RIC transplant (Fludar-
abine 150mg/m2 plus Melphalan 140mg/m2:6; Fludarabine
plus Melphalan plus Antithymocyte Globulin:2; Fludarabine
180mg/m2 plus Bulsufan 10mg/m2 plus Antithymocyte
globulin 5mg/kg:1).
Results: In the myeloablative conditioning group (n¼5), all
the patients presented marrow engraftment; one relapsed.
Three patients presented grade II-IV acute graft versus host
disease, and four developed severe chronic graft versus host
disease. Four patients died, and the only survivor was 10
years-old. Median survival was 479 days. In RIC group (n¼9),
engraftment didn't occur in one patient (which had spleno-
megaly of 18 cm at the time of transplantation), and another
three relapsed. The other seven patients remained alive and
free of disease, with median survival of 750 days (34-1872;
P¼ 0,000123).
Conclusion: In spite of the limited number of patients in this
study, data suggest that RIC regimens improved survival in
HSCT for myeloﬁbrosis in our center, even with a slightely
greater relapse risk. Except for very young patients, this
strategy should be considered for further investigation.361
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is an established therapy for malignant and nonma-
lignant hematologic disorders. Reduced-intensity condi-
tioning (RIC) regimens have expanded the use of HSCT to the
elderly patients and to patients that are otherwise ineligible
for conventional transplants. However, RIC HSCT still
remains associated with a signiﬁcant morbidity and
mortality and the careful assessment of risks and beneﬁts
before transplantation is essential. Major factors which
inﬂuence non-relapse mortality (NRM) and overall survival
(OS) after HSCT are diagnosis, type of transplant and the
patient's risk proﬁle, which includes age and presence ofcomorbidities. The use of the hematopoietic cell trans-
plantation-speciﬁc comorbidity index (HSCT-CI) has been
proposed to predict the probability of non-relapse mortality
(NRM) and overall survival (OS) following HSCT. Since its
development, HSCT-CI has been evaluated at different insti-
tutions for various hematologic diseases. We performed
a single-center retrospective study to assess the prognostic
value of HSCT-CI on transplant outcomes in a cohort of
patients undergoing RIC HSCT. We analyze patients receiving
a RIC HSCT between January 2005 and December 2010. The
median patient age at the time of transplantation was 57
years (range: 19-75 years). The patient diagnoses included
AML (32%), NHL (28%), MM (15%), MDS (10%), HD (5%), CLL
(5%), ALL (3%), MPD (1%) and nonmalignant hematologic
(1%). The median pre-transplantation HSCT-CI score was 2
(range: 0-9). Among 133 patients, OS at 2 years was 36%. The
2 yr OS is 34%, 33% and 41% in the low-, intermediate-, and
high-risk HSCT-CI groups respectively (P ¼ .72). The corre-
sponding NRM at 2 years was 39%, 41% and 38% (P ¼ .85).
Further subgroup analysis (patient age, diagnosis, condi-
tioning, remission status and prior stem cell transplant)
disclosed no signiﬁcant differences in the OS prediction by
the HCT-CI score. In conclusion, we found no predictive value
of HSCT-CI for the determination of 2-year OS or 2-year NRM
in allogeneic HSCT receiving reduced-intensity condition.362
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Prolonged hospitalization exposes patients (pts) under-
going allogeneic hematopoietic cell transplantation (HCT) to
risks of iatrogenic complications and results in signiﬁcant
morbidity and mortality as well as expense, however, there
are limited data on risk factors that contribute to length of
stay (LOS) in HCT pts.
663 pts underwent HCT from 1/1997 to 12/2011. Among
663 pts, 49 died in the hospital within 6 weeks (wks) of
transplant and were excluded, leaving 614 pts, median age 44
(range 18-71 years), for analysis. Pts underwent HCT for acute
myeloid leukemia (n¼258), acute lymphoblastic leukemia
(n¼98), myelodysplastic syndrome (n¼87), chronic myeloid
leukemia (n¼78), non Hodgkin lymphoma (n¼55), aplastic
anemia (n¼20), Hodgkin disease, myeloproliferative
neoplasm, and plasma cell disorders (remaining n¼18). The
majority of pts underwent myeloablative transplant (n¼599,
97.6%); 15 (2.4%) had a reduced-intensity transplant. 317
(51.6%)pts receiveda transplant fromarelateddonor, 250 from
an unrelated donor (40.7%) and 47 (7.7%) received cord blood.
153 pts (25%) were identiﬁed to have a prolonged LOS,
deﬁned as 6 wks. In univariable analyses, variables asso-
ciated with LOS included: poor performance status (PS)
(odds ratio [OR] 1.31 per 10 point decrease on Karnofsky
scale, P ¼ .017), unrelated donor transplant (OR 3.45,
P < .001), cord blood transplant (OR 7.86, P < .001), HLA
mismatch (OR 4.45, P < .001), and CD34+ cell dose (median
